Get the Stockscreener App
2.57
2.39%
0.06
After Hours:
2.55
-0.02
-0.78%
Aclaris Therapeutics Inc stock is traded at $2.57, with a volume of 495.32K.
It is up +2.39% in the last 24 hours and down -21.17% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
See More
Previous Close:
$2.51
Open:
$2.54
24h Volume:
495.32K
Relative Volume:
0.20
Market Cap:
$275.04M
Revenue:
$31.25M
Net Income/Loss:
$-88.48M
P/E Ratio:
-2.0236
EPS:
-1.27
Net Cash Flow:
$-79.63M
1W Performance:
+4.05%
1M Performance:
-21.17%
6M Performance:
+94.70%
1Y Performance:
+117.80%
1-Day Range:
$2.46
$2.59
1-Week Range:
$2.31
$2.59
52-Week Range:
$0.9515
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.57 | 275.04M | 31.25M | -88.48M | -79.63M | -1.27 |
|
TMO
Thermo Fisher Scientific Inc
|
559.65 | 214.07B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
238.36 | 172.16B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
147.36 | 42.09B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.36 | 35.82B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
419.26 | 34.33B | 3.84B | 866.24M | 792.60M | 10.37 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 12.7% in December - MarketBeat
Hair Treatment Drug Market Is Booming Worldwide | 3S Bio, Inc.,AbbVie,Aclaris Therapeutics, Inc.,Cipla, Inc. - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.00 Average Target Price from Brokerages - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Jane Street Group LLC - MarketBeat
Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Highlights Drug Progress and Financial Strength - TipRanks
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Awards Stock Options to Attract Top Talent - MSN
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Hair Loss Treatment Market Is Booming Worldwide 2024-2031 | Viviscal, Cipla Inc., Aclaris Therapeutics - openPR
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by State Street Corp - Defense World
Aclaris sells OLUMIANT royalties and milestones to OMERS life sciences - MSN
HC Wainwright & Co. Upgrades Aclaris Therapeutics (ACRS) - MSN
ACRS LOSS NOTICE: ROSEN, A LEADING FIRM, Announces Filing of Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the FirmACRS - AccessWire
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Update - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 27.4% in December - MarketBeat
Research Analysts Issue Forecasts for ACRS FY2024 Earnings - Defense World
HC Wainwright Has Bullish Estimate for ACRS FY2024 Earnings - MarketBeat
Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma - Investing.com Nigeria
Aclaris Therapeutics shares upgraded to Buy on strong growth potential in AD and asthma By Investing.com - Investing.com South Africa
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Buy at HC Wainwright - Defense World
HighTower Advisors LLC Trims Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday - Benzinga
Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls - Nasdaq
HC Wainwright Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to "Buy" - MarketBeat
Analysts Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $8.80 - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $8.80 - MarketBeat
Fmr LLC Cuts Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Financial Review: Aclaris Therapeutics (NASDAQ:ACRS) versus Theratechnologies (NASDAQ:THTX) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short Interest - Defense World
Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan - MSN
Aclaris Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 59.0% in November - MarketBeat
Jacobs Levy Equity Management Inc. Takes Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Aclaris Therapeutics, Inc. announced that it expects to receive $79.999999 million in funding from a group of investors - Marketscreener.com
Finance Watch: PIPEs Still Key Even As FOPO Fundraising Climbs - News & Insights
Wayne’s Aclaris Therapeutics Signs Exclusive Licensing Deal with Chinese Biotech - MSN
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Connor Clark & Lunn Investment Management Ltd. Grows Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Decrease in Short Interest - Defense World
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):